


hCAI/II-IN-5

Cat. No.:	HY-147955
CAS No.:	2428389-67-5
Molecular Formula:	C ₂₁ H ₁₈ Cl ₂ N ₈ O ₄ S ₂
Molecular Weight:	581.45
Target:	Carbonic Anhydrase; AChE
Pathway:	Metabolic Enzyme/Protease; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	hCAI/II-IN-5 (compound MZ8) is a potent hCA I and hCA II (human carbonic anhydrase isoenzymes I and II) inhibitor, with IC ₅₀ values of 37.88 and 45.23 nM, respectively. hCAI/II-IN-5 also shows inhibition profile against α-Glycosidase and AChE, with IC ₅₀ values of 48.98 and 420.14 nM, respectively. hCAI/II-IN-5 can be used for the research of many diseases such as diabetes, Alzheimer's disease, heart failure, ulcer, and epilepsy ^[1] .
IC ₅₀ & Target	IC ₅₀ : 37.88 ± 0.9956 nM (hCA II), 45.23 ± 0.9684 nM (hCA I), 48.98 ± 0.9407 nM (α-GLY), 420.14 ± 0.9759 nM (AChE); K _i : 40.35 ± 5.74 nM (hCA II), 50.04 ± 5.76 nM (α-GLY), 51.67 ± 4.76 nM (hCA I), 363.96 ± 32.87 nM (AChE) ^[1]

REFERENCES

[1]. Lolak N, et al. Synthesis, characterization, inhibition effects, and molecular docking studies as acetylcholinesterase, α-glycosidase, and carbonic anhydrase inhibitors of novel benzenesulfonamides incorporating 1,3,5-triazine structural motifs. *Bioorg Chem.* 2020 Jul;100:103897.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA